Abstract 412P
Background
A significant proportion of newly diagnosed advanced NSCLC patients does not receive a first-line platinum doublet due to unfavorable clinical characteristics.
Methods
We retrospectively collected data on 221 EGFR/ALK negative and PD-L1 <50% patients [median age 79 (range 56-92) years, M/F 165(74.6%)/56(25.4%), PS 0/1/≥2 23(10.4%)/94(42.5%)/103(47.1%), adenoK/squamous/large-cell/NOS 107(48.4%)/94(42.5%)/9(4.1%)/11(5%), median of 2 serious comorbidities] with stage IIIB-IV NSCLC treated with a first-line single agent. Clinicians were asked about the criteria according to which treatment selection was made and what percentage of patients did not receive a first-line platinum-based chemotherapy.
Results
A median of 25% (range 10%-30%) of newly diagnosed NSCLC did not receive a first-line platinum combination. The main clinical criteria according to which decision was made were older age (76.5%), comorbidities (72%), low PS (55.2%) and familiar or social issues (10%). Single-agent treatment consisted of gemcitabine (Gem 10%), oral standard vinorelbine (Vin 8.2%), oral metronomic vinorelbine (MetV 78.6%) and other (O 3.2%). Median time-to-progression (TTP) and overall survival (OS) of single agent treatments were Gem 4.5, Vin 4.5, MetV 5, O 5 months and Gem 9, Vin 9, MetV 10, O 10.5 months respectively. Overall grade 3-4 toxicities were lower with MetV (8%) than with Gem (13.6%), Vin (16.6%) and O (14.3%). Median TTP and OS without grade 3-4 toxicity were Gem 5, Vin 4.5, MetV 6.5, O 5.5 months and Gem 10, Vin 10, MetV 12, O 12 months respectively. Dose delays (Gem 41%, Vin 16.6%, MetV 13.8%, O 28.6%) and dose reductions (Gem 31.8%, Vin 33.3%, MetV 17.8%, O 28.6%) were less frequent with MetV.
Conclusions
We confirmed that up to 30% of newly diagnosed advanced EGFR/ALK negative and PD-L1 <50% NSCLC patients do not receive a first-line platinum doublet. Main clinical selection criteria were older age (>70years), comorbidities and low (≥2) PS. An oral treatment was frequently proposed with MetV being the preferred alternative chosen by clinicians due to the excellent safety profile.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
193P - First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Exploratory survival analyses by change in post treatment CA 19-9
Presenter: Andrew Dean
Session: e-Poster Display Session
194P - Nab-paclitaxel plus capecitabine as first-line treatment for patients with recurrence or metastatic biliary tract cancer
Presenter: Jun Zhou
Session: e-Poster Display Session
370P - Bespoke circulating tumour DNA assay for the detection of minimal residual disease in esophageal adenocarcinoma patients
Presenter: Emma Ococks
Session: e-Poster Display Session
390P - A real-world clinical study of camrelizumab in the treatment of esophageal cancer
Presenter: Guoping Sun
Session: e-Poster Display Session
203P - Characterization of renal cell carcinoma (RCC) with VHL mutation
Presenter: Yanrui Zhang
Session: e-Poster Display Session
204P - Prospective observational study on pazopanib in patients treated for advanced or metastatic renal cell carcinoma (RCC) in Asia, North Africa and Middle East countries: Final analysis of PARACHUTE study
Presenter: Ravindran Kanesvaran
Session: e-Poster Display Session
205P - A study on organ preservation in muscle invasive urinary bladder cancer patients with intensity modulated radiotherapy and concurrent single agent cisplatin in south Indian population
Presenter: Himani Manchala
Session: e-Poster Display Session
206P - Mutational signature in urothelial carcinoma with TP53 mutation
Presenter: Huan Liu
Session: e-Poster Display Session
207P - Concordance of genomic alterations by next-generation sequencing in tumour tissue versus circulating tumour DNA in urothelial carcinoma
Presenter: wang Wang
Session: e-Poster Display Session
208P - Prognostic factors and outcomes of non-seminomatous germ cell tumours of testis: Experience from a tertiary cancer centre in India
Presenter: Lekha Nair
Session: e-Poster Display Session